Therefore, caution should be exercised in fully characterizing the tumor (e.g., CD4 or CD8; does the tumor itself bear KLRK1, or is it expressed by the infiltrating T cells (29)) to ascertain whether KLRK1 both as a biomarker and a potential treatment target is beneficial or detrimental (28). This evidence concerns the gene CD8A and neoplasm.